VECT-HORUS Completes Its €12 Million Fund-raising Operation
VECT-HORUS, a biotech company that designs and develops vectors that enable therapeutic molecules or imaging agents to be delivered to key organs, has just closed its Series D fund-raising. The first round, held in September 2020, raised €6.7 million and a second round in December 2020 added €5.3 million from private investors, bringing the total amount raised in these two rounds to €12 million.
This second funding round strengthens the company's capital so it can pursue its ambitious programmes, focusing on identifying new vectors, developing theragnostic (therapeutic and diagnostic) agents in a clinical setting and validating its technology for delivering therapeutic antibodies and nucleic acids.